CORDIS
EU research results

CORDIS

English EN

Image-Guided Surgery (IGS) and Personalised Postoperative Immunotherapy To Improving Cancer Outcome

Objective

The basic concept of our proposal is to develop nanoparticle-based encapsulated libraries of different immunotherapeutic biomolecules for treatment after surgery as part of a novel cancer management strategy. The current state-of-art for the management of cancer starts with surgery, after identification of an accessible tumour mass. Surgery remains an effective treatment option for many types of cancer today and it is considered curative treatment for most solid tumours. It forms part of a multidisciplinary approach used in conjunction with radiotherapy or chemotherapy. These approaches, however, have several limitations, including inability of surgical resection to affect distal metastatic disease, toxicity to healthy tissues with chemotherapy and lack of effectiveness of radiation therapy in more aggressive tumours. The observation that cancer can relapse months or years after initial surgery implies that micrometastases still resides within the body in a latent state. Our proposal is to take cancer therapy to beyond state-of-art by implementing techniques which will take us into new directions. This includes a) new methods to identify immune gene profiles and biomarkers b) transgenic mouse models where the complex interactions that underlie immune function can be visualised as multiplexed events in real time and c) the use of nanoparticle-based libraries of immune modulating reagent combinations. There are three key objectives within this project: i) to use immune gene signatures to monitor disease progression and therapeutic efficacy of immunotherapy combinations on nanoparticle-based platforms, ii) to optimise the platform to encapsulate libraries of immune components for more personalised, accurate and timely delivery of the payload to its intended target and iii) to optimise the overall cancer management process of image-guided surgery followed by postoperative immunotherapy so that we can ultimately provide a lifetime of protection against cancer.

Coordinator

PERCUROS BV

Address

Plesmanlaan 1
2333 Bz Leiden

Netherlands

Activity type

Private for-profit entities (excluding Higher or Secondary Education Establishments)

EU Contribution

€ 255 374,28

Participants (13)

Sort alphabetically

Sort by EU Contribution

Expand all

ACADEMISCH ZIEKENHUIS LEIDEN

Netherlands

EU Contribution

€ 680 998,08

TECHNISCHE UNIVERSITEIT DELFT

Netherlands

EU Contribution

€ 212 811,90

UNIVERSITA DEGLI STUDI DI CAMERINO

Italy

EU Contribution

€ 258 061,32

TECOBIOSCIENCES GMBH

Germany

EU Contribution

€ 249 216,48

UNIVERSITEIT VAN AMSTERDAM

Netherlands

EU Contribution

€ 127 687,14

UNIVERSITETET I BERGEN

Norway

EU Contribution

€ 286 275,24

HELSE BERGEN HF*HAUKELAND UNIVERSITY HOSPITAL

Norway

EU Contribution

€ 286 275,24

ECOLE POLYTECHNIQUE FEDERALE DE LAUSANNE

Switzerland

EU Contribution

€ 265 226,76

THE UNIVERSITY OF SHEFFIELD

United Kingdom

EU Contribution

€ 546 575,76

UNIVERSITEIT MAASTRICHT

Netherlands

EU Contribution

€ 127 687,14

JENACELL GMBH

Germany

EU Contribution

€ 249 216,48

MEDRES-MEDICAL RESEARCH GMBH

Germany

EU Contribution

€ 249 216,48

ERASMUS UNIVERSITAIR MEDISCH CENTRUM ROTTERDAM

Netherlands

EU Contribution

€ 127 687,14

Project information

Grant agreement ID: 675743

Status

Ongoing project

  • Start date

    1 January 2016

  • End date

    31 December 2019

Funded under:

H2020-EU.1.3.1.

  • Overall budget:

    € 3 922 309,44

  • EU contribution

    € 3 922 309,44

Coordinated by:

PERCUROS BV

Netherlands